Skip to main content

Clinical Trials Using Beta-Adrenergic Antagonist

Review the clinical trials studying beta-adrenergic antagonist on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-14 of 14

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Status: Active
Location: 6 locations
Propranolol for the Treatment of Adult Patients with Kaposi Sarcoma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Propranolol, Pembrolizumab and Chemotherapy for Tumor Re-sensitization and Treatment of Patients with PD-L1 Positive Metastatic or Unresectable Triple Negative Breast Cancer
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Propranolol in Combination with Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Propranolol and Chemoradiation Therapy for the Treatment of Patients with Esophageal Cancer
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Naltrexone and Propranolol in Combination with Standard of Care Ipilimumab and Nivolumab for the Treatment of Stage II-III Melanoma
Status: Active
Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients with Multiple Myeloma, Plasma Cell Leukemia or Low Risk Myelodysplastic Syndrome
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Propranolol Hydrochloride and Pembrolizumab in Treating Patients with Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
Status: Temporarily Closed to Accrual
Location: 4 locations
Topical Timolol Solution for Improving Wound Healing Time after Mohs Surgery in Patients with Cutaneous Melanoma
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Stress Reduction Intervention versus Standard of Care in Patients with Stage II-III Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery, The PRESERVE Study
Status: Active
Location: 7 locations
Carvedilol and/or Empagliflozin for the Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-Directed Therapy, HER2HEART-US Trial
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
ACE Inhibitors and Beta Blockers for the Protection of the Heart among Patients Receiving Intensive Chemotherapy for Acute Myeloid Leukemia
Status: Active
Location: University of Virginia Cancer Center, Charlottesville, Virginia
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
Status: Active
Location: Banner University Medical Center - Tucson, Tucson, Arizona
Understanding Heart Risks of People With HER2-Positive Breast Cancer That Has Spread
Status: Active
Location: 378 locations